vs

Side-by-side financial comparison of MYRIAD GENETICS INC (MYGN) and PERDOCEO EDUCATION Corp (PRDO). Click either name above to swap in a different company.

PERDOCEO EDUCATION Corp is the larger business by last-quarter revenue ($211.6M vs $209.8M, roughly 1.0× MYRIAD GENETICS INC). On growth, PERDOCEO EDUCATION Corp posted the faster year-over-year revenue change (20.0% vs -0.4%). Over the past eight quarters, PERDOCEO EDUCATION Corp's revenue compounded faster (12.2% CAGR vs 1.9%).

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

Perdoceo Education Corporation (PRDO) is a public company that owns five for-profit universities in the United States: American Intercontinental University, Colorado Technical University, California Southern University, Trident University International, and University of St. Augustine for Health Sciences. The company was previously known as Career Education Corporation.

MYGN vs PRDO — Head-to-Head

Bigger by revenue
PRDO
PRDO
1.0× larger
PRDO
$211.6M
$209.8M
MYGN
Growing faster (revenue YoY)
PRDO
PRDO
+20.3% gap
PRDO
20.0%
-0.4%
MYGN
Faster 2-yr revenue CAGR
PRDO
PRDO
Annualised
PRDO
12.2%
1.9%
MYGN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MYGN
MYGN
PRDO
PRDO
Revenue
$209.8M
$211.6M
Net Profit
Gross Margin
70.0%
Operating Margin
-2.7%
19.8%
Net Margin
Revenue YoY
-0.4%
20.0%
Net Profit YoY
EPS (diluted)
$-0.09
$0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MYGN
MYGN
PRDO
PRDO
Q4 25
$209.8M
$211.6M
Q3 25
$205.7M
$211.9M
Q2 25
$213.1M
$209.6M
Q1 25
$195.9M
$213.0M
Q4 24
$210.6M
$176.4M
Q3 24
$213.3M
$169.8M
Q2 24
$211.5M
$166.7M
Q1 24
$202.2M
$168.3M
Net Profit
MYGN
MYGN
PRDO
PRDO
Q4 25
Q3 25
$-27.4M
$39.9M
Q2 25
$-330.5M
$41.0M
Q1 25
$-100.0K
$43.7M
Q4 24
Q3 24
$-22.1M
$38.3M
Q2 24
$-36.7M
$38.4M
Q1 24
$-26.0M
$39.4M
Gross Margin
MYGN
MYGN
PRDO
PRDO
Q4 25
70.0%
Q3 25
69.9%
Q2 25
71.2%
Q1 25
68.5%
Q4 24
71.7%
Q3 24
70.2%
Q2 24
69.6%
Q1 24
68.1%
Operating Margin
MYGN
MYGN
PRDO
PRDO
Q4 25
-2.7%
19.8%
Q3 25
-11.3%
24.1%
Q2 25
-154.5%
24.5%
Q1 25
-14.8%
24.3%
Q4 24
-18.6%
21.1%
Q3 24
-9.4%
26.4%
Q2 24
-17.3%
27.6%
Q1 24
-13.8%
27.5%
Net Margin
MYGN
MYGN
PRDO
PRDO
Q4 25
Q3 25
-13.3%
18.8%
Q2 25
-155.1%
19.6%
Q1 25
-0.1%
20.5%
Q4 24
Q3 24
-10.4%
22.5%
Q2 24
-17.4%
23.0%
Q1 24
-12.9%
23.4%
EPS (diluted)
MYGN
MYGN
PRDO
PRDO
Q4 25
$-0.09
$0.55
Q3 25
$-0.29
$0.60
Q2 25
$-3.57
$0.62
Q1 25
$0.00
$0.65
Q4 24
$-0.47
$0.46
Q3 24
$-0.24
$0.57
Q2 24
$-0.41
$0.57
Q1 24
$-0.29
$0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MYGN
MYGN
PRDO
PRDO
Cash + ST InvestmentsLiquidity on hand
$149.6M
$111.0M
Total DebtLower is stronger
$119.9M
Stockholders' EquityBook value
$368.0M
$972.4M
Total Assets
$706.6M
$1.2B
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MYGN
MYGN
PRDO
PRDO
Q4 25
$149.6M
$111.0M
Q3 25
$145.4M
$159.5M
Q2 25
$74.4M
$172.1M
Q1 25
$91.8M
$132.1M
Q4 24
$102.4M
$109.1M
Q3 24
$99.9M
$238.0M
Q2 24
$97.3M
$127.9M
Q1 24
$104.3M
$125.8M
Total Debt
MYGN
MYGN
PRDO
PRDO
Q4 25
$119.9M
Q3 25
$119.5M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
MYGN
MYGN
PRDO
PRDO
Q4 25
$368.0M
$972.4M
Q3 25
$372.8M
$997.9M
Q2 25
$388.1M
$984.6M
Q1 25
$704.9M
$970.3M
Q4 24
$701.1M
$959.5M
Q3 24
$731.7M
$935.4M
Q2 24
$740.5M
$899.5M
Q1 24
$760.0M
$866.1M
Total Assets
MYGN
MYGN
PRDO
PRDO
Q4 25
$706.6M
$1.2B
Q3 25
$728.1M
$1.3B
Q2 25
$677.3M
$1.3B
Q1 25
$1.0B
$1.3B
Q4 24
$1.0B
$1.2B
Q3 24
$1.1B
$1.1B
Q2 24
$1.1B
$1.1B
Q1 24
$1.1B
$1.1B
Debt / Equity
MYGN
MYGN
PRDO
PRDO
Q4 25
0.33×
Q3 25
0.32×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MYGN
MYGN
PRDO
PRDO
Operating Cash FlowLast quarter
$10.6M
$40.1M
Free Cash FlowOCF − Capex
$37.9M
FCF MarginFCF / Revenue
17.9%
Capex IntensityCapex / Revenue
1.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$216.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MYGN
MYGN
PRDO
PRDO
Q4 25
$10.6M
$40.1M
Q3 25
$21.1M
$41.2M
Q2 25
$-13.6M
$78.8M
Q1 25
$-16.3M
$65.1M
Q4 24
$6.6M
$17.6M
Q3 24
$700.0K
$51.0M
Q2 24
$2.6M
$38.5M
Q1 24
$-18.6M
$54.5M
Free Cash Flow
MYGN
MYGN
PRDO
PRDO
Q4 25
$37.9M
Q3 25
$39.4M
Q2 25
$76.0M
Q1 25
$63.4M
Q4 24
$16.0M
Q3 24
$50.0M
Q2 24
$37.7M
Q1 24
$53.3M
FCF Margin
MYGN
MYGN
PRDO
PRDO
Q4 25
17.9%
Q3 25
18.6%
Q2 25
36.3%
Q1 25
29.8%
Q4 24
9.1%
Q3 24
29.4%
Q2 24
22.6%
Q1 24
31.7%
Capex Intensity
MYGN
MYGN
PRDO
PRDO
Q4 25
1.1%
Q3 25
0.9%
Q2 25
1.3%
Q1 25
0.8%
Q4 24
0.9%
Q3 24
0.6%
Q2 24
0.5%
Q1 24
0.7%
Cash Conversion
MYGN
MYGN
PRDO
PRDO
Q4 25
Q3 25
1.03×
Q2 25
1.92×
Q1 25
1.49×
Q4 24
Q3 24
1.33×
Q2 24
1.00×
Q1 24
1.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MYGN
MYGN

Segment breakdown not available.

PRDO
PRDO

CTU$107.0M51%
AIUS$60.8M29%
University Of St Augustine For Health Sciences Llc$43.7M21%
Other$1.1M1%

Related Comparisons